HIV vaccine formulation
AssigneeJanssen Vaccines & Prevention B.V.
InventorsThierry-Thien Nguyen, Mark Bruner
Life of this patent
Estimating the term…
Abstract
Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions.
Claims20
A method for storing a composition, the method comprising providing the composition comprising, relative to the total volume of the composition:
- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein or of a mixture of at least two HIV gp140 proteins;
- b. 2% to 15% (w/v) sorbitol;
- c. 0.01 to 0.05% (w/v) polysorbate 20;
- and
- d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0,
- and storing the composition at 2-8° C. for at least one day.
A method for storing a composition, the method comprising providing the composition comprising, relative to the total volume of the composition:
- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 2 or of a mixture of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO:
- 1 and an HIV gp140 protein comprising the amino acid sequence of SEQ NO:
- 2;
- b. 5% or 12% (w/v) sorbitol;
- c. 0.02% (w/v) polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5;
- and
- e. an aluminum phosphate adjuvant,
- and storing the composition at 2-8° C. for at least one day.
A composition comprising an HIV gp140 protein, a sorbitol, a polysorbate and a histidine.
Dependencies are inferred from the claim text.